

References for the section on Stand-down times

- Allen, B. G., Bodeker, K. L., et al. (2019). First-in-human phase 1 clinical trial of pharmacological ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma. *Clinical Cancer Research*, 25(22), 6590. <http://dx.doi.org/10.1158/1078-0432.CCR-19-0594>
- Andreucci, M., Solomon, R., et al. (2014). Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention. *Biomed Res Int*, 2014741018. <http://dx.doi.org/10.1155/2014/741018>
- Ayatollahi, V., Dehghanpoor-Farashah, S., et al. (2017). Effect of intravenous vitamin C on post-operative pain in uvulopalatopharyngoplasty with tonsillectomy. *Clin Otolaryngol*, 42(1), 139-143. <http://dx.doi.org/10.1111/coa.12684>
- Bael, T. E., Peterson, B. L., et al. (2008). Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. *Melanoma research*, 18, 147-151. <http://dx.doi.org/10.1097/CMR.0b013e3282f2a7ae>
- Bahr, R. L., Wilson, D. C. (2014). The Impact of High-Dose Vitamin C on Blood Glucose Testing in 18F-FDG PET Imaging. *J Nucl Med Technol*, 43(1), 70-71. <http://dx.doi.org/10.2967/jnmt.114.140335>
- Carr, A. C., Cook, J. (2018). Intravenous Vitamin C for Cancer Therapy - Identifying the Current Gaps in Our Knowledge. *Frontiers in physiology*, 9, 1182. <https://doi.org/10.3389/fphys.2018.01182>
- Du, J., Cieslak 3rd, J. A., et al. (2015). Pharmacological Ascorbate Radiosensitizes Pancreatic Cancer. *Cancer Res*, 75(16), 3314-3326. <http://dx.doi.org/10.1158/0008-5472.CAN-14-1707>
- Elsa, A., Ubawaki, S. (2005). Ketamine anaesthesia following premedication of rabbits with vitamin C. *J Vet Sci*, 6(3), 239-241. <http://www.ncbi.nlm.nih.gov/pubmed/16131828>
- Goldfarb, S., McCullough, P. A., et al. (2009). Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology. *Mayo Clin Proc*, 84(2), 170-179. <https://www.ncbi.nlm.nih.gov/pubmed/19181651>
- Herst, P. M., Broadley, K. W. R., et al. (2012). Pharmacological concentrations of ascorbate radiosensitize glioblastoma multiforme primary cells by increasing oxidative DNA damage and inhibiting G2/M arrest. *Free Radic Biol Med*, 52(8), 1486-1493. <http://dx.doi.org/10.1016/j.freeradbiomed.2012.01.021>
- Hoffer, L. J., Robitaille, L., et al. (2015). High-Dose Intravenous Vitamin C Combined with Cytotoxic Chemotherapy in Patients with Advanced Cancer: A Phase I-II Clinical Trial. *PLoS One*, 10(4), e0120228. <http://dx.doi.org/10.1371/journal.pone.0120228>
- Jackson, J. A., Hunninghake, R., et al. (2006). False Positive Finger Stick Blood Glucose Readings After High-Dose Intravenous Vitamin C. *Journal of Orthomolecular Medicine*, 21(4), 188-190. <https://riordanclinic.org/wp-content/uploads/2014/12/89024578.pdf>
- Kawada, H., Sawanobori, M., et al. (2014). Phase I Clinical Trial of Intravenous L-ascorbic Acid Following Salvage Chemotherapy for Relapsed B-cell non-Hodgkin's Lymphoma. *Tokai J Exp Clin Med*, 39(3), 111-115. <http://www.ncbi.nlm.nih.gov/pubmed/25248425>
- Ma, Y., Chapman, J., et al. (2014). High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. *Science Translational Medicine*, 6(222), 222ra18. <http://dx.doi.org/10.1126/scitranslmed.3007154>
- Monti, D. A., Mitchell, E., et al. (2012). Phase I evaluation of intravenous ascorbic Acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. *PLoS One*, 7(1), e29794. <http://dx.doi.org/10.1371/journal.pone.0029794>
- Najafpour, A., Sadeghi-Hashjin, G. (2007). Vitamin C pre-medication enhances the anaesthetic effect of ketamine-xylazine combination in the rat. *Arch Med Sci*, 3340-343. <http://journals.indexcopernicus.com/abstract.php?icid=681119>

Schoenfeld, J. D., Sibenaller, Z. A., et al. (2017). O₂- and H₂O₂-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. *Cancer Cell*, 31(4), 487-500.e8. <http://dx.doi.org/10.1016/j.ccr.2017.02.018>

Spargias, K., Alexopoulos, E., et al. (2004). Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. *Circulation*, 110(18), 2837-2842. <http://dx.doi.org/10.1161/01.CIR.0000146396.19081.73>

Stephenson, C. M., Levin, R. D., et al. (2013). Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. *Cancer Chemother Pharmacol*, 72(1), 139-146. <http://dx.doi.org/10.1007/s00280-013-2179-9>

Surasi, D. S., Bhambhani, P., et al. (2014). 1⁸F-FDG PET and PET/CT patient preparation: a review of the literature. *J Nucl Med Technol*, 42(1), 5-13. <http://dx.doi.org/10.2967/jnmt.113.132621>

Tang, Z., Du, X., et al. (2000). Effects of drugs on glucose measurements with handheld glucose meters and a portable glucose analyzer. *Am. J. Clin. Pathol.*, 113(1), 75-86. <http://dx.doi.org/10.1309/QAW1-X5XW-BVRQ-5LKQ>

Vasudevan, S., Hirsch, I. B. (2014). Interference of intravenous vitamin C with blood glucose testing. *Diabetes Care*, 37(5), e93-e94. <http://dx.doi.org/10.2337/dc13-2452>

Wang, Z. J., Hu, W. K., et al. (2014). The effect of intravenous vitamin C infusion on periprocedural myocardial injury for patients undergoing elective percutaneous coronary intervention. *Can J Cardiol*, 30(1), 96-101. <http://dx.doi.org/10.1016/j.cjca.2013.08.018>

Welsh, J. L., Wagner, B. A., et al. (2013). Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. *Cancer Chemother Pharmacol*, 71:765-775. <http://dx.doi.org/10.1007/s00280-013-2070-8>

Zhao, H., Zhu, H., et al. (2018). The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. *Leukemia research*, 66, 1-7. <https://doi.org/10.1016/j.leukres.2017.12.009>